Last updated on May 2020

Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer


Brief description of study

ADU-CL-20 is an open-label, multicenter Phase 2 clinical trial to evaluate the efficacy and safety of intratumoral ADU-S100 (also referred to as MIW815) administered with pembrolizumab in the first-line setting. The population will consist of adults with PD-L1 positive recurrent or metastatic HNSCC.

Clinical Study Identifier: NCT03937141

Find a site near you

Start Over

James Graham Brown Cancer Center

Louisville, KY United States
3.7miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.